Literature DB >> 19653829

Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin.

Isamu Hongo1, Tadashi Baba, Kanenari Oishi, Yuh Morimoto, Teruyo Ito, Keiichi Hiramatsu.   

Abstract

Panton-Valentine leukocidin (PVL) has long been considered a critical toxin in severe Staphylococcus aureus infection. PVL presumably breaches the body's defense system by lysing human polymorphonuclear cells (PMNs). Recently, however, bioactive peptides--phenol-soluble modulins (PSMs)--have been proposed as the main player in the lysis of PMNs, rather than PVL. This study aimed to resolve uncertainty concerning the cause of the lysis of human PMNs by using recombinant PVL toxins and PVL-neutralizing monoclonal antibodies. The recombinant PVL toxins showed strong lytic activity against human but not murine neutrophils. Moreover, the lytic activity of culture supernatants of strains USA400 MW2 and USA300 FPR3757 were completely neutralized by anti-PVL monoclonal antibodies. In contrast, phenol-soluble modulin alpha 3--the most potent PSM peptide--failed to lyse human PMNs at the concentrations contained in the culture supernatants. Phenol-soluble modulin alpha 3 did, however, enhance PVL-mediated lysis of human PMNs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653829     DOI: 10.1086/605332

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors:  Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

Review 3.  Novel targeted immunotherapy approaches for staphylococcal infection.

Authors:  Michael Otto
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 4.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

5.  Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants.

Authors:  Shawna F Graves; Scott D Kobayashi; Kevin R Braughton; Binh An Diep; Henry F Chambers; Michael Otto; Frank R Deleo
Journal:  Microbes Infect       Date:  2010-02-19       Impact factor: 2.700

Review 6.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

7.  Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins.

Authors:  Jason Yamaki; Timothy Synold; Annie Wong-Beringer
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 8.  Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors.

Authors:  András N Spaan; Jos A G van Strijp; Victor J Torres
Journal:  Nat Rev Microbiol       Date:  2017-04-19       Impact factor: 60.633

9.  Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains.

Authors:  Min Li; Gordon Y C Cheung; Jinhui Hu; Decheng Wang; Hwang-Soo Joo; Frank R Deleo; Michael Otto
Journal:  J Infect Dis       Date:  2010-11-04       Impact factor: 5.226

Review 10.  Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus.

Authors:  Richard R Watkins; Michael Z David; Robert A Salata
Journal:  J Med Microbiol       Date:  2012-06-28       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.